Major Players - Blood Based Biomarker Industry

A biomarker is an objective measure that captures what is happening in a cell or an organism at a given moment. Biomarkers can serve as early warning systems for health. A blood-based biomarkers (biological marker in the patient’s blood) is a measurable DNA, RNA or protein component that indicates diseases such as cancer, Alzheimer’s disease.

As of 2022, the global Blood Based Biomarkers Market is estimated to be valued at U.S. $ 18,803.3 Million and is expected to exhibit a CAGR of 12.8% during the years (2022-2030)

Key Companies in the Blood Based Biomarker Industry:

1) Hoffman-La Roche AG

Hoffman-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company known for operating worldwide. Roche is the fifth largest pharmaceutical company in the world by revenue, and also the leading provider of cancer treatments globally. The company was founded in the year 1896, and the headquarters are located in Basel, Switzerland. The company was founded by Fritz Hoffmann-La Roche.

In March 2021, Roche announced its plans of acquiring GenMark Diagnostics for U.S. $ 1.8 Billion. In September 2021, the company announced it would acquire German Biotech Group, TIB Molbiol.

2) Eisai Co. Ltd

Eisai Co. Ltd. is a Japanese pharmaceutical company that manufactures products like Actonel, Aloxi, Belviq, Dayvigo, Halaven, Iomeron, Methylcobal and others. Eisai has over 10,000 employees. The company was founded in the year 1941, and the headquarters are located in Bunkyo-ku, Tokyo, Japan. The company is listed in the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

As of April 2022, the company has completed the acquisition of Arteryex Shares, making it the subsidiary of Eisai.

3) C2N Diagnostics

C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company. The company focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company was founded in the year 2007, and the headquarters are located in St Louis, Missouri.

As of November 2022, C2N Diagnostics introduced the PrecivityAD2 Blood Test, in order to facilitate earlier and more accurate diagnosis of AD pathology.

4) GENFIT

GENFIT is a French Biotechnology Company. Its research and clinical trials, in the fields of cardiovascular diseases and liver diseases, in particular of metabolic origin. Genfit is also present in the development of medical diagnostic technology. GENFIT has facilities in Lille and Paris, France, Zurich, Switzerland, and Cambridge, MA, USA. The company was founded in the year 1999, and the headquarters are located in Loos, Hauts-de-France.

As of September 2022, the company had announced its plans of acquiring Clinical-stage Biopharmaceutical Company Versantis, expanding its portfolio in Liver Diseases.

5) Diadem

Diadem is a diagnostic company that carries on specific research and developments on early peripheral markers of Alzheimer’s disease into technology. The company has developed a unique solution to one of the biggest problems in Neurodegenerative disease and in early, non-invasive and cost-effective diagnosis in Alzheimer’s disease. The company was founded in the year 2012, and the headquarters are located in London.

In May 2022, the company partnered up with Dementias platform UK to advance diagnosis and treatment of Alzheimer’s disease.